Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 抑制剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NXPHTpY6S3m2b4TvfIlkKEG|c3H5 NHvNZYYyOCCwTR?= M2n6elczKGh? M{j6b2ROW09? M3jXNnBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NYTXeldROjR7MEC4O|M>
HT-29 Mn[5R5l1d3SxeHnjJGF{e2G7 MVixNEBvVQ>? NHHLb2g4OiCq M2HxOWROW09? M2m0NHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= M37PbVI1QTByOEez
HT-29 MlPZR5l1d3SxeHnjJGF{e2G7 NWXsOXBXOTBibl2= NHHSUFQ4OiCq NEG0[VFFVVOR M4XOdXBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NIPwNlEzPDlyMEi3Ny=>
PC3 NV:yOXBFU2mwYYPlJGF{e2G7 MYGxNFAhdk1? NG\meosyKGh? MXXEUXNQ M3nHUnBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u MXyyNVk4QDZ6Mx?=
PC3 M2\3UGtqdmG|ZTDBd5NigQ>? NEXMW3AyODBibl2= MUCxJIg> MkDiSG1UVw>? MlW0SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NYX2VldNOjF7N{i2PFM>
PC3 NXPBbXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxMlUh|ryP NEniNFMyKGh? NVXQcJZtTE2VTx?= NVnTbY9NUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NEn3TJYzOTl5OE[4Ny=>
HEK293 M2e0UGZ2dmO2aX;uJGF{e2G7 MkDWNVAxKG6P NX3LeJNWQCCq NWLmboRITE2VTx?= NUPaeJU1UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N M{O1VlIyPTN7M{Cx
BT-20 MWPLbY5ie2ViQYPzZZk> NFTiXGYzOCEQvF2= NIL2O4xFVVOR M1;lVWRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w NX;xWoQ5OjF|NUO1OVE>
U937 MUXBcpRq[mGldHXybYFtKEG|c3H5 M{TGVVUxKM7:TR?= MXG0PEBp Mn7ESG1UVw>? M3rpUWlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MUiyNVE1OjFyNh?=
U937 MWXBcpRq[mGldHXybYFtKEG|c3H5 MYG1NEDPxE1? Mke1OFghcA>? NGroT5pFVVOR MnPwSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NYj3VHN{OjFzNEKxNFY>
U937 MV\BcpRq[mGldHXybYFtKEG|c3H5 MkHEOVAh|ryP MkXpOFghcA>? NHPSPJlFVVOR NYe2R2c6TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? MkHTNlEyPDJzME[=
MCF-7 M2\MemF2fG:yaHHnfUBCe3OjeR?= NEDNZ4c{OCCwTR?= MkO0OEBp NF;GVnZFVVOR MVvJcoR2[2W|IHH1eI9xcGGpeR?= NHPRbGgzODB{OEGzOC=>
U87MG NU\KbndsU2mwYYPlJGF{e2G7 MnnaNUDPxE1? NXHEe5lXPiCq NWPreoN2TE2VTx?= M{W2R3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MWmxPVg1QDRyNB?=
U87MG NU\hNWhnU2mwYYPlJGF{e2G7 NUHVcXFEOSEQvF2= MlP5OkBp NVj2eFN5TE2VTx?= M3L3WHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u NGjISpcyQTh2OESwOC=>
U87MG MkLIT4lv[XOnIFHzd4F6 NHH5OY4yKM7:TR?= NHHoOoo3KGh? MmS0SG1UVw>? M4\rXmRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NXHQTVhGOTl6NEi0NFQ>
U87MG M{jXOGtqdmG|ZTDBd5NigQ>? NWDyXmNCOSEQvF2= NX2xN5hSPiCq NUniWmdOTE2VTx?= M3i1ZWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NInNVnAyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MnmzRZV1d3CqYXf5JGF{e2G7 MV:wMlIh|ryP MkLSNlQhcA>? MnvTSG1UVw>? M1T4U2lv\HWlZYOgZZV1d3CqYXf5 MYixPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 NEjsRmtCfXSxcHjh[5khSXO|YYm= M3PJ[lAvOiEQvF2= MYSyOEBp M3m1U2ROW09? NUnt[VJDUW6mdXPld{BifXSxcHjh[5k> NWTtcnFbOTh|OUG5OFk>
H4 MknySpVv[3Srb36gRZN{[Xl? MUKwMlIh|ryP Mm\hNlQhcA>? NV;4c4U1TE2VTx?= MW\JcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz M3\1V|E5ODJ2NUi0
HeLa Ml\nSpVv[3Srb36gRZN{[Xl? NEDLbGsyODBibl2= M{PRfVM3KGh? MVLEUXNQ MmLoTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MV2xO|U3OzN6NR?=
HeLa MUHGeY5kfGmxbjDBd5NigQ>? Ml60NVAxKG6P NHK1WWc{PiCq NWLrZZZrTE2VTx?= M3WwPWlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? MUWxO|U3OzN6NR?=
HeLa NEnaNWtHfW6ldHnvckBCe3OjeR?= MU[xNFAhdk1? Ml7ON|YhcA>? MkLPSG1UVw>? NIH6ZopKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> MnvsNVc2PjN|OEW=
SYF NUXES29ZTnWwY4Tpc44hSXO|YYm= MlK2NVAxKG6P M4HUc|I1KGh? NXHRO5ZQTE2VTx?= MoHUTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NWLhTpJxOTd3NkOzPFU>
SYF NXfNeJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknTNVAxKG6P M1vwVlI1KGh? MX3EUXNQ NIGxfoRKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NX7ke4k4OTd3NkOzPFU>
HEK293T MV\BcpRqfmm{YXygRZN{[Xl? M{[wfFEhdk1? NGjZO4Q1KGR? NX21XYd{TE2VTx?= NVfZbZduUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> MV[xO|Q5PTVyMR?=
HEK293T NULvNGh7SW62aY\pdoFtKEG|c3H5 NFSzepkyKG6P NF74T4I1KGR? M{OwTGROW09? NIXVTItKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MnW2NVc1QDV3MEG=
PBMC M1PibGZ2dmO2aX;uJGF{e2G7 M2HpUFEhdk1? NVnNSIxpOTRiZB?= MVTEUXNQ MlzXVoVlfWOnczDDR3I2KGSnboPpeJk> MYCxO|Q5PTVyMR?=
PBMC NFHN[41HfW6ldHnvckBCe3OjeR?= NUPKTHNOOSCwTR?= NUnOdo1xOTRiZB?= NFz3NJVFVVOR MX;Ec4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> Mo\ONVc1QDV3MEG=
HEK293 cells MXHLbY5ie2ViQYPzZZk> MVy1NEBvVQ>? M3LZdlQ2KG2rbh?= NYHB[FR7TE2VTx?= MWPJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O MYKxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MmHaSpVv[3Srb36gRZN{[Xl? M165blExOCCwTR?= MUO0JIg> Mme0SG1UVw>? MVTJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MUmxO|EzQDJ4Mh?=
Human mixed lymphocyte NYfNcVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[3fVUhdk1? MYHEUXNQ Mlq3TWM2OD1zLk[gcm0v M2HLNFE3OTh3OE[1
Lewis rat lymph node cells NGm5fYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC1JO69VQ>? NHS3TY9FVVOR MVTJR|UxRTJwNjFOwG0> MkLuNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NUHXRZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTtcIJMOTBibl2= NHqw[pc4OiCq MmLoSG1UVw>? MWLJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NWSwZlVnOTByMkG5OFg>
MRK-nu-1 NWLObpZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHNXVKSzVyPUCuPFQ2KHCP MVrTRW5ITVJ?
OCUB-M M2DaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXRTJNKSzVyPUWuNlQheE1? MnvqV2FPT0WU
SF539 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XaNmlEPTB;MUGuOkBxVQ>? M3TkWHNCVkeHUh?=
ES4 NIiwcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jWPWlEPTB;MkGuOUBxVQ>? NEPR[4JUSU6JRWK=
RL95-2 M{KwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjzfHRxUUN3ME2xNFcheE1? NF7adpJUSU6JRWK=
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPDSm0xUUN3ME20NlMheE1? MlLpV2FPT0WU
Daudi NX\XXHdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR|NDDwUS=> M1\v[HNCVkeHUh?=
NTERA-S-cl-D1 NUG1dHBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ZbHRKSzVyPUS0N{BxVQ>? NVK0VIFMW0GQR1XS
OS-RC-2 NX;x[JlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZ3MjDwUS=> M1HSeHNCVkeHUh?=
VA-ES-BJ M1\Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyTWM2OD15MkOgdG0> MUfTRW5ITVJ?
GR-ST NFvxcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTh2NjDwUS=> MX3TRW5ITVJ?
SW872 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThTlFnUUN3ME24OFYheE1? NH3tXJJUSU6JRWK=
NOS-1 NHKySJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDKOHZKSzVyPUi3NUBxVQ>? MlnVV2FPT0WU
MC116 NWfsPWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHBTWM2OD17OEWgdG0> NY\UXYtOW0GQR1XS
NCI-H1355 NHrhRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mz[mlEPTB;MT6wNUBvVQ>? MUHTRW5ITVJ?
RPMI-8226 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnSVpRKSzVyPUGuNVkhdk1? NUTJV|Z7W0GQR1XS
TE-15 M1WxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnwTlJtUUN3ME2xMlM3KG6P MWXTRW5ITVJ?
Ramos-2G6-4C10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCW25KSzVyPUGuOFYhdk1? NWX6eXVSW0GQR1XS
KU812 NX3MOmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwMEGgcm0> NYjxNXBpW0GQR1XS
EW-1 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[xTYM2UUN3ME2yMlE4KG6P MWHTRW5ITVJ?
KS-1 NYe5OndHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4bYRxUUN3ME2yMlQ2KG6P MX3TRW5ITVJ?
SK-LMS-1 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwNEmgcm0> MknBV2FPT0WU
TGBC1TKB NYexdJAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLcJJKSzVyPUKuOlkhdk1? M4ToPHNCVkeHUh?=
TE-6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonZTWM2OD1{Lke3JI5O NI\qS3ZUSU6JRWK=
ETK-1 NGHmU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLmUHU6UUN3ME2yMlgzKG6P MVnTRW5ITVJ?
BE-13 M{f0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWPINKSzVyPUKuPVkhdk1? MkTGV2FPT0WU
A3-KAW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfLepdKSzVyPUKuPVkhdk1? NUDHXXptW0GQR1XS
TE-10 M4faWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMzDuUS=> M2HWV3NCVkeHUh?=
DOHH-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzPWlEPTB;Mz6zOUBvVQ>? MYLTRW5ITVJ?
ES6 NIj1XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrVTWM2OD1|LkSzJI5O M4\iV3NCVkeHUh?=
OPM-2 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwMUWgcm0> MWXTRW5ITVJ?
SH-4 NW\qRXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDi[IJDUUN3ME20MlM1KG6P Mln4V2FPT0WU
NB13 NVLVXppyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\F[XNKSzVyPUSuN|Yhdk1? NI\VWWhUSU6JRWK=
HUTU-80 NILxZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLUWlJ1UUN3ME20MlQzKG6P MXLTRW5ITVJ?
CCRF-CEM MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli5TWM2OD12Lkm0JI5O NF7Yc2JUSU6JRWK=
TGBC24TKB NHXSO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTVwNUGgcm0> MnnJV2FPT0WU
697 NFKxbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqxNGViUUN3ME22MlI5KG6P M33ZVHNCVkeHUh?=
J-RT3-T3-5 M{\BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqxTWM2OD14LkS2JI5O MnOzV2FPT0WU
KALS-1 M1S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3MTWM2OD14LkW2JI5O MUPTRW5ITVJ?
no-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfoTWM2OD15LkK5JI5O M4PjSnNCVkeHUh?=
SK-NEP-1 NWnnNm11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwN{mgcm0> M{TMNnNCVkeHUh?=
L-540 NGLqbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFyLkSyJI5O M3\ZTHNCVkeHUh?=
JiyoyeP-2003 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H6U2lEPTB;MUCuPVQhdk1? MWLTRW5ITVJ?
HH M175cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnTOoRKSzVyPUGxMlM6KG6P M2TOb3NCVkeHUh?=
SR MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nTTWlEPTB;MUGuOFUhdk1? MVnTRW5ITVJ?
QIMR-WIL NGW5XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\KV2lEPTB;MUGuPFUhdk1? NGjjSplUSU6JRWK=
A4-Fuk MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHDRYYzUUN3ME2xN{4yOiCwTR?= NVSwOXJMW0GQR1XS
CESS Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r6e2lEPTB;MUOuNVMhdk1? NIXPXGRUSU6JRWK=
KE-37 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\uRZdKSzVyPUG2MlA4KG6P M4eyZXNCVkeHUh?=
SK-UT-1 M{frWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPUVmdKSzVyPUG2MlgyKG6P MnO1V2FPT0WU
SIG-M5 NIrzTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHGfYVKSzVyPUG3MlI2KG6P NHzscYFUSU6JRWK=
HT M2L5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD1zNz62JI5O NHOzRZJUSU6JRWK=
DEL NGXXWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQ[|ZkUUN3ME2xO{46QSCwTR?= NW\EeVFTW0GQR1XS
SK-PN-DW MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnQfpE5UUN3ME2yNE4zOyCwTR?= MYjTRW5ITVJ?
RPMI-8402 M2DPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJzLke3JI5O NYXRWop5W0GQR1XS
RPMI-6666 NGXVdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4bmlEPTB;MkSuOFIhdk1? MnPxV2FPT0WU
NCI-H720 M17iU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;tTWM2OD1{NT60NUBvVQ>? MnTmV2FPT0WU
EW-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHyTWM2OD1{Nj64O{BvVQ>? MWDTRW5ITVJ?
BL-70 M3GzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M133NmlEPTB;MkiuN|ghdk1? Mn7SV2FPT0WU
SF126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3FNI5KSzVyPUOwMlM5KG6P MlfOV2FPT0WU
BC-1 NVnpXIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNzLkK2JI5O MlTWV2FPT0WU
MHH-PREB-1 NVfvdpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWxZWl4UUN3ME2zNk41PCCwTR?= MWfTRW5ITVJ?
A101D MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m4SmlEPTB;M{KuOlIhdk1? NUP0[FRGW0GQR1XS
NMC-G1 M3j6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN|Lk[3JI5O M13UV3NCVkeHUh?=
LB1047-RCC M4XjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXKbZAzUUN3ME2zOE43QSCwTR?= MYfTRW5ITVJ?
EM-2 M3q4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfQSYpUUUN3ME2zPE42OyCwTR?= NGX5RlFUSU6JRWK=
COLO-684 NGrudYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DQUGlEPTB;M{muPEBvVQ>? MnvIV2FPT0WU
Becker Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jYTmlEPTB;NEGuNFUhdk1? MUHTRW5ITVJ?
BL-41 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3LNHRKSzVyPUSzMlY3KG6P NUXiZW13W0GQR1XS
MDA-MB-134-VI MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD12ND6wNkBvVQ>? NH3WW45USU6JRWK=
L-363 NW\mVnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnwS5dKSzVyPUS0Mlc{KG6P MVPTRW5ITVJ?
ECC4 M{TicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7OTo43UUN3ME20OE44QCCwTR?= M2DwVnNCVkeHUh?=
A388 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjBZVZKSzVyPUS0MlgzKG6P NVi3UIY1W0GQR1XS
HEL NFrNPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13IN2lEPTB;NEmuO|khdk1? NUTnSoVqW0GQR1XS
RKO NV\teIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfUcHZbUUN3ME21NE4zQSCwTR?= MUjTRW5ITVJ?
KINGS-1 NIW4[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\0XndKSzVyPUWxMlU2KG6P NUfx[lJoW0GQR1XS
EB-3 M{nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGwfHJtUUN3ME21Nk43PyCwTR?= M3fVdHNCVkeHUh?=
ARH-77 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTV{Lkigcm0> M{PxdHNCVkeHUh?=
GCIY M4HpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml35TWM2OD13Mz60OkBvVQ>? NYiyUGhpW0GQR1XS
NCI-H1304 M3rRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M376ZWlEPTB;NUeuNlIhdk1? MWnTRW5ITVJ?
KARPAS-299 NY\pZYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvUOFdKSzVyPU[xMlgzKG6P NHzpZVFUSU6JRWK=
IA-LM M4fIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDu[3N5UUN3ME22PE4yOyCwTR?= NHvtdYZUSU6JRWK=
GI-1 M4jEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTdyLkO5JI5O NUfpNoNQW0GQR1XS
TE-11 NEnEcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTd5LkG3JI5O MkfsV2FPT0WU
LS-411N M1zte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe4[4lKSzVyPUe3MlU4KG6P NH63RXZUSU6JRWK=
no-11 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDudIpKSzVyPUizMlI1KG6P MVvTRW5ITVJ?
MV-4-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1mwXGlEPTB;OEOuO|Mhdk1? NWLoTINSW0GQR1XS
BV-173 NF;WPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfaVlJKSzVyPUizMlk4KG6P M{m1cHNCVkeHUh?=
CMK Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPMTWM2OD16ND6xOkBvVQ>? NEDFfHpUSU6JRWK=
LC4-1 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHwTWM2OD16Nj63NkBvVQ>? MmG4V2FPT0WU
COR-L279 M3mxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTh5LkK1JI5O MlnGV2FPT0WU
NCI-H209 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17wdmlEPTB;OEeuOFEhdk1? NF:ydlVUSU6JRWK=
Raji NFe0S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfOTWM2OD16OT63NkBvVQ>? MWDTRW5ITVJ?
LB996-RCC MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnUUldKSzVyPUmzMlQ{KG6P MULTRW5ITVJ?
NCI-H526 M3\hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnfmlEPTB;OUOuOVkhdk1? M2T2c3NCVkeHUh?=
KGN MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;2SWlEPTB;OU[uNlkhdk1? MlGwV2FPT0WU
MOLT-4 M1fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILYSGNKSzVyPUm2Mlc6KG6P MUPTRW5ITVJ?
PF-382 NGG5XXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGzTWM2OD17Nj63PUBvVQ>? MV\TRW5ITVJ?
BC-3 M3PnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy3RohKSzVyPUm5MlE5KG6P MnjoV2FPT0WU
KARPAS-422 M3v2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFyMj6wPUBvVQ>? NELXd5NUSU6JRWK=
SBC-1 NEnYTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkTWM2OD1zMEeuO|Uhdk1? NVzLXWFyW0GQR1XS
LC-1F MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTrTWM2OD1zMEiuNFUhdk1? NGnLXZNUSU6JRWK=
GB-1 M2XaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4RY1KSzVyPUGwPU4xOiCwTR?= NIXIS2tUSU6JRWK=
SNB75 M2T2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTyTWM2OD1zMUmuOlkhdk1? Mn3FV2FPT0WU
BB65-RCC M4fRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojGTWM2OD1zMUmuPVMhdk1? M3PHOXNCVkeHUh?=
NCI-N87 NXf2WlBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD1zMkGuPVghdk1? M13rXXNCVkeHUh?=
IST-MEL1 NX;Lc3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;QTWM2OD1zMkKuN|ghdk1? NVuwbpY2W0GQR1XS
HOP-62 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofXTWM2OD1zMk[uPFkhdk1? NEeyR4xUSU6JRWK=
ACN NUPjWI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fJcGlEPTB;MUS2Mlc2KG6P M2TGdHNCVkeHUh?=
DMS-114 M3zadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzTWM2OD1zNUCuOlchdk1? NGfXZnNUSU6JRWK=
MLMA NHLtN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:3fY5KSzVyPUG1PU45QCCwTR?= MVjTRW5ITVJ?
HT-144 NHG1TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF4NT60N{BvVQ>? NUnLb|dbW0GQR1XS
C2BBe1 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PoZWlEPTB;MU[3Mlc3KG6P NWnyVGhPW0GQR1XS
L-428 M1TvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTF5Nz63JI5O NFXmTHFUSU6JRWK=
DU-4475 M17v[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF6Nz62PEBvVQ>? M1njS3NCVkeHUh?=
CP67-MEL MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:1PWlEPTB;MUm5MlM5KG6P MX3TRW5ITVJ?
MEG-01 NXvVUnNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTXVmhVUUN3ME2yNFEvQTZibl2= MWTTRW5ITVJ?
IST-SL2 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ZUWlEPTB;MkC4MlY{KG6P M1vEZ3NCVkeHUh?=
ES8 NVnqVnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHweYFKSzVyPUKyOU46PCCwTR?= NGrCV29USU6JRWK=
COLO-800 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PkcWlEPTB;MkO1MlI5KG6P M{LwOHNCVkeHUh?=
MFH-ino M1zTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ|NT64OEBvVQ>? NFLWW5FUSU6JRWK=
OVCAR-4 NVnX[Jd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ|Nz6yOEBvVQ>? MXnTRW5ITVJ?
PSN1 NUj0b3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq4fHlrUUN3ME2yOFIvPzFibl2= MUPTRW5ITVJ?
EW-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHsepNsUUN3ME2yOFMvOSCwTR?= MVzTRW5ITVJ?
HCC1599 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTp[GpNUUN3ME2yOlEvPDdibl2= NX;jbYZEW0GQR1XS
SJSA-1 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ5MT60OkBvVQ>? MnTpV2FPT0WU
ST486 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ITWM2OD1{OU[uNVQhdk1? MVjTRW5ITVJ?
NOMO-1 M4XSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;qN2lEPTB;M{CwMlIyKG6P NUPKNmExW0GQR1XS
MN-60 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInqU5FKSzVyPUOwOU4{OiCwTR?= M2\6[nNCVkeHUh?=
HCC1187 NGrHPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNyNz6yOUBvVQ>? NWLycpZ4W0GQR1XS
SW982 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD1|MUSuO|Uhdk1? MnvtV2FPT0WU
LB647-SCLC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Jb3RKSzVyPUOyPE44OSCwTR?= MoHmV2FPT0WU
HC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjnTWM2OD1|M{WuOUBvVQ>? MUTTRW5ITVJ?
EHEB M3;Fc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPDTWM2OD1|M{euOVIhdk1? MWDTRW5ITVJ?
TUR NHHmNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN4Mz65OUBvVQ>? NHfZUo9USU6JRWK=
LU-139 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjrUmxKSzVyPUO3PE4xOiCwTR?= NYTZTokxW0GQR1XS
NB1 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyT2dKSzVyPUO4OE41PSCwTR?= M3Pt[HNCVkeHUh?=
BB30-HNC NYDufYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WzVWlEPTB;M{i4MlMzKG6P MYXTRW5ITVJ?
HAL-01 NXm1UY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riZmlEPTB;M{i5MlI3KG6P NI\xRYtUSU6JRWK=
K5 NVXhRYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4flRmlEPTB;NEGxMlM4KG6P MXvTRW5ITVJ?
MZ2-MEL MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrhd|FJUUN3ME20NVMvPjRibl2= MYPTRW5ITVJ?
RXF393 NU\3NJNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37YNGlEPTB;NEG2MlQ2KG6P M3;wWHNCVkeHUh?=
NCI-H1648 NGPh[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfmbVNKSzVyPUSxO{42OyCwTR?= NUfjOoI4W0GQR1XS
TE-12 NXjRVY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2yTWM2OD12M{SuNlYhdk1? NES1TZlUSU6JRWK=
EoL-1- NWLzZ3JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPaTWM2OD12M{euPVghdk1? NEfvWVRUSU6JRWK=
JAR MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnrfpYyUUN3ME20N|gvPjJibl2= MX3TRW5ITVJ?
DSH1 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuwTVBKSzVyPUS1PE46OSCwTR?= MUTTRW5ITVJ?
NCI-H187 NYLLU2UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K5O2lEPTB;NE[yMlgyKG6P NGj6XG9USU6JRWK=
HCE-4 M4DPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFna[Y1KSzVyPUS3O{43PiCwTR?= NXP4OlE5W0GQR1XS
8-MG-BA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wTWM2OD13OEGuOVIhdk1? NX7F[2M2W0GQR1XS
KLE NFTGd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XoV2lEPTB;NUi1MlIhdk1? Mnu0V2FPT0WU
KNS-42 NV3Z[IRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP3cVk4UUN3ME21PFYvQDFibl2= M1nTUXNCVkeHUh?=
MSTO-211H MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTZyOT63OEBvVQ>? NVLJR3NrW0GQR1XS
GDM-1 M4nVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQUldJUUN3ME22NVQvODlibl2= NUHO[Y5HW0GQR1XS
TE-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPUSFBKSzVyPU[0Ok4yOiCwTR?= NIr6WolUSU6JRWK=
BT-474 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[xSXNSUUN3ME22OFcvODZibl2= NI\JV2xUSU6JRWK=
KARPAS-45 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTtb4F1UUN3ME22OFcvPiCwTR?= M{\ZOXNCVkeHUh?=
MOLT-16 NFL0NYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDPPZhyUUN3ME22OFcvQTNibl2= MYLTRW5ITVJ?
KURAMOCHI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqTWM2OD14NUeuOVEhdk1? MX7TRW5ITVJ?
K-562 NEfMWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELDeplKSzVyPU[2PU42OSCwTR?= M3jsb3NCVkeHUh?=
EKVX NWfJW4N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fMbmlEPTB;NkeyMlcyKG6P MVHTRW5ITVJ?
GAK NEjQeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfmXpo4UUN3ME22O|UvOyCwTR?= NHXWUXdUSU6JRWK=
NCI-SNU-5 NV;P[oZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ToZmlEPTB;NkmwMlAyKG6P M2K1V3NCVkeHUh?=
NCI-H2126 NYrUbpo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC4eXpKSzVyPUeyOk45PyCwTR?= NYnPVGRTW0GQR1XS
CTV-1 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HNWlEPTB;N{S0Mlkhdk1? NWPYeVZuW0GQR1XS
SW962 NIP2UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzSPXVsUUN3ME23OFgvPDRibl2= MnS4V2FPT0WU
MONO-MAC-6 NYXXWFV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7he2hnUUN3ME23OVYvQTNibl2= MYHTRW5ITVJ?
NCI-H748 M3r4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrVbVZKSzVyPUe1PE46QSCwTR?= NUX1dVZpW0GQR1XS
NCI-H524 NELNXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\DTWM2OD15OECuO|Mhdk1? Mlv5V2FPT0WU
LS-123 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTd7NT62PUBvVQ>? NXu5[FUyW0GQR1XS
NB7 M2jvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;3UWt7UUN3ME24NVQvOTRibl2= NXS3XnBkW0GQR1XS
LS-1034 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvoSFVKSzVyPUiyPE46QCCwTR?= NWG4SGJQW0GQR1XS
TE-5 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjkTWM2OD16OEOuOVYhdk1? MkLMV2FPT0WU
A704 NXzJ[3QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTh7OT6xOUBvVQ>? M4XGRXNCVkeHUh?=
TK10 NU\hdXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zYWGlEPTB;OUG2MlA{KG6P MYDTRW5ITVJ?
NCI-H345 M1S0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\vTWM2OD17NEOuNlIhdk1? M1O2TXNCVkeHUh?=
CGTH-W-1 NEPPZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17jUWlEPTB;OUS4MlE{KG6P Mln5V2FPT0WU
NCI-H510A M4fFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj2T3lKSzVyPUm4OU4yOiCwTR?= M1TKXXNCVkeHUh?=
NCI-H1963 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX0VWZCUUN3ME2xMlA{Ojl{IN88US=> Mk\SV2FPT0WU
SCC-3 M37BRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4emlEPTB;MT6wN|QyPCEQvF2= M1fK[3NCVkeHUh?=
EW-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zoO2lEPTB;MT6wPFc1OyEQvF2= MnXyV2FPT0WU
CPC-N NVHxe2gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j4bmlEPTB;MT6wPFgh|ryP M2DtbHNCVkeHUh?=
NCI-H1417 M1[xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPsO2pKSzVyPUGuNVIzPiEQvF2= M164TXNCVkeHUh?=
DG-75 M3KzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;BTWM2OD1zLkG2Nlg2KM7:TR?= NYjC[XNFW0GQR1XS
HD-MY-Z NVjkUHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwMU[0NVYh|ryP M2X1VXNCVkeHUh?=
ATN-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3frT2lEPTB;MT6yOlIxQSEQvF2= MYnTRW5ITVJ?
KM-H2 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\EcmZ6UUN3ME2xMlI3PDB6IN88US=> NWHsWG1kW0GQR1XS
NCI-H2081 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMk[2N|ch|ryP MnX0V2FPT0WU
HL-60 NF7WdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLkR|lKSzVyPUGuNlY6PTlizszN MofyV2FPT0WU
DB NWL5c2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSV25JUUN3ME2xMlI4OjR{IN88US=> NUjwVXFXW0GQR1XS
NCI-H1522 NVnI[JdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJOWJNUUN3ME2xMlI5QDh5IN88US=> MnPIV2FPT0WU
AM-38 NFzOb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LQ[2lEPTB;MT6zNFczKM7:TR?= MnvxV2FPT0WU
NCI-H446 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3WV3VtUUN3ME2xMlMzOTJzIN88US=> Mn35V2FPT0WU
SU-DHL-1 NYHyOXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi3ZnYxUUN3ME2xMlMzQDBzIN88US=> MXLTRW5ITVJ?
NH-12 NInzRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPVmlEPTB;MT6zOlM4PCEQvF2= MkfGV2FPT0WU
DMS-79 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLwTWM2OD1zLkO2PFY3KM7:TR?= M2PsW3NCVkeHUh?=
NCI-H716 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFfGlEPTB;MT6zPFk5PiEQvF2= MYDTRW5ITVJ?
ML-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rMZmlEPTB;MT60NVUzQSEQvF2= MXjTRW5ITVJ?
NB10 NXXlWnk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNE[2N|Ih|ryP NEj2dXpUSU6JRWK=
ONS-76 NUXBWmNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fhbWlEPTB;MT61N|U3QSEQvF2= MoTWV2FPT0WU
LOUCY MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2wTWM2OD1zLkW0OlU4KM7:TR?= NF:2NXlUSU6JRWK=
SCLC-21H Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nb2RKSzVyPUGuOVg2QDJizszN MoXmV2FPT0WU
TGW M1LjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L1cWlEPTB;MT62N|k4PSEQvF2= MWfTRW5ITVJ?
LXF-289 NYG2WmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXmSmpNUUN3ME2xMlc{OjZ6IN88US=> NW[0ZmRwW0GQR1XS
BB49-HNC MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MniyTWM2OD1zLkezOVg3KM7:TR?= MX;TRW5ITVJ?
NCI-H747 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHScYJKSzVyPUGuO|U{PDZizszN M2\Cd3NCVkeHUh?=
LU-165 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3YNXc5UUN3ME2xMlg1QTh4IN88US=> NGS1OYlUSU6JRWK=
OMC-1 NYPYN|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH2bY16UUN3ME2xMlk2ODZ4IN88US=> NGX0fYxUSU6JRWK=
RCC10RGB NWLhZ|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PNeWlEPTB;MT65OVgyPyEQvF2= NWfLb5ZOW0GQR1XS
SW684 NEnQfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwOU[wPVkh|ryP NYrTWmlOW0GQR1XS
TE-8 NWTTOFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmxdWNOUUN3ME2yMlA2PTV7IN88US=> M{G3S3NCVkeHUh?=
SK-N-DZ NIn0dGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfVSZFKSzVyPUKuNVMzPzRizszN MYDTRW5ITVJ?
EVSA-T M2fHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTsTWM2OD1{LkG3N|E2KM7:TR?= MULTRW5ITVJ?
KASUMI-1 NGP5fI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwMUi4NVUh|ryP NGfiOnhUSU6JRWK=
NKM-1 NFy5VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHtWHVOUUN3ME2yMlI2PDd{IN88US=> NUPXRlhmW0GQR1XS
CAL-148 NVfYXoRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;LTWM2OD1{LkOzOlE1KM7:TR?= MoP0V2FPT0WU
NCI-H64 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nv[mlEPTB;Mj6zOFI{OiEQvF2= NYq2blRyW0GQR1XS
KNS-81-FD NHfJcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwM{[2NkDPxE1? M3\RNnNCVkeHUh?=
KM12 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG1NG1KSzVyPUKuOFA5OzlizszN M3XiOnNCVkeHUh?=
SW954 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDsNnBqUUN3ME2yMlQ4Pzd7IN88US=> MWHTRW5ITVJ?
NCI-H1395 NFLxWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPER2ZKSzVyPUKuOVI3PDVizszN NXflW5JNW0GQR1XS
DJM-1 M4HBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PLXWlEPTB;Mj62NFY{KM7:TR?= M4fVUHNCVkeHUh?=
COLO-668 M3j6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DjS2lEPTB;Mj64NlY6PSEQvF2= M1uwcXNCVkeHUh?=
NCI-H1436 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwOEW2NVUh|ryP NXrKRZFRW0GQR1XS
LB2241-RCC M{\rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwOE[4N|kh|ryP NGTPSplUSU6JRWK=
GT3TKB MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVSWlEPTB;Mj64PVA2PSEQvF2= M17FdXNCVkeHUh?=
COLO-824 M4e3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGxW|hKSzVyPUKuPFk4PjhizszN NIHLfHFUSU6JRWK=
ES1 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwOEm4O|kh|ryP NHezVnNUSU6JRWK=
LB771-HNC MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX23XVBrUUN3ME2yMlkxQTR4IN88US=> NVeyNZR{W0GQR1XS
GI-ME-N Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\1UFNKSzVyPUOuNFA6ODRizszN MUTTRW5ITVJ?
NALM-6 NITRbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWyUGM1UUN3ME2zMlAxQTN|IN88US=> NXnOUohPW0GQR1XS
LU-134-A NF6yW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxS2xKSzVyPUOuNFU1OjVizszN NWG4dJc2W0GQR1XS
DMS-153 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX70O3hDUUN3ME2zMlA2QDJ2IN88US=> MoXLV2FPT0WU
MZ1-PC NHXUS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHITWM2OD1|LkC5NFc5KM7:TR?= Mn[1V2FPT0WU
NCI-H1155 M2\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQ[|RKSzVyPUOuNVE3OSEQvF2= M2LjVnNCVkeHUh?=
CAS-1 M2r4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTNwMUO3NFch|ryP NFvqblhUSU6JRWK=
D-502MG NE\aZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwMUSzPUDPxE1? M4j3XnNCVkeHUh?=
NCI-H2141 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNwMUe0OVIh|ryP M4W2TnNCVkeHUh?=
NB6 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGeweo9KSzVyPUOuNVgzPTlizszN MYnTRW5ITVJ?
NCCIT M1q5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMkG4NFkh|ryP M2jKPHNCVkeHUh?=
NB69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnmVWhKSzVyPUOuN|E5QTFizszN NYfTZ5V2W0GQR1XS
JVM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrWZmV[UUN3ME2zMlM3PDN|IN88US=> NVzqcGpCW0GQR1XS
K052 NHXsS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnoTWM2OD1|LkO3PVY5KM7:TR?= NXL2ZWpGW0GQR1XS
HCC2157 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LJUWlEPTB;Mz61N|IzQCEQvF2= MmnwV2FPT0WU
KMOE-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrNTWM2OD1|LkW0NlQzKM7:TR?= M{fnSnNCVkeHUh?=
SF268 NH3xOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwN{G1OVQh|ryP Ml35V2FPT0WU
CHP-126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjS[mdSUUN3ME2zMlc3PDV6IN88US=> MWHTRW5ITVJ?
CP66-MEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCWmpKSzVyPUOuO|kxQTRizszN MlnVV2FPT0WU
NCI-H69 M4riTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjBXVFUUUN3ME20MlAyQTN4IN88US=> NWfKO3pNW0GQR1XS
A253 NYHzWHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjOdFFKSzVyPUSuNFIyODFizszN NHnGWHdUSU6JRWK=
NB14 NXHG[pNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDrTWM2OD12LkGwOFc6KM7:TR?= NIPUTVhUSU6JRWK=
NCI-H1694 M2\6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:w[YhUUUN3ME20MlE{OTF{IN88US=> NGD3fHlUSU6JRWK=
NCI-H2196 NUnRfI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\KdWVUUUN3ME20MlE4OTZ7IN88US=> M3[4TnNCVkeHUh?=
TE-9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPTVYNKSzVyPUSuNVc2QDJizszN NYDYb|BtW0GQR1XS
D-283MED NVT2fmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW3TWM2OD12LkG4PFQh|ryP NUHuSGtEW0GQR1XS
OCI-AML2 NXPsenBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwMUm0PFkh|ryP MVrTRW5ITVJ?
D-263MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXGbGdKSzVyPUSuNlI6PjFizszN NYK3blc4W0GQR1XS
MPP-89 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTGb5R7UUN3ME20MlI4OzB2IN88US=> MWLTRW5ITVJ?
LAMA-84 M1nB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH3TWM2OD12LkOwOFIyKM7:TR?= NVnG[GFuW0GQR1XS
LB373-MEL-D NVLhXJE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC0TWM2OD12LkO2O|g6KM7:TR?= NHLO[HJUSU6JRWK=
UACC-257 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXDbGlKSzVyPUSuN|k2OzRizszN NIjqcphUSU6JRWK=
MC-CAR NGjoU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TSVmlEPTB;ND60N|k6KM7:TR?= M{PuPXNCVkeHUh?=
COLO-320-HSR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LUXWlEPTB;ND60OFQzPyEQvF2= M{\0W3NCVkeHUh?=
P30-OHK M1zhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPjTWM2OD12Lk[2OVgyKM7:TR?= Mm\PV2FPT0WU
UACC-812 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsdIxMUUN3ME20MlY6OTZzIN88US=> MkXDV2FPT0WU
CTB-1 NYjJepppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PETWlEPTB;ND63NVU2PSEQvF2= NWfTbItqW0GQR1XS
ALL-PO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlZoh2UUN3ME20Mlg1ODd5IN88US=> M2jiOnNCVkeHUh?=
SK-MEL-2 M{jpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD12Lki2PVU2KM7:TR?= Mn[0V2FPT0WU
TC-YIK MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnW[4FxUUN3ME20Mlk4QTR{IN88US=> M3vZc3NCVkeHUh?=
NCI-H1882 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwfphKSzVyPUWuNFIxODFizszN MmTBV2FPT0WU
MHH-CALL-2 NUDmcVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzsU5l[UUN3ME21MlA2ODR{IN88US=> NWrUPVRbW0GQR1XS
U-87-MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i0S2lEPTB;NT6wPVQ3PiEQvF2= MWDTRW5ITVJ?
NCI-H1092 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD13LkK2OVU2KM7:TR?= NV\E[mRvW0GQR1XS
TE-441-T NHzWbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ThNmlEPTB;NT6yO|gzKM7:TR?= M3;DRXNCVkeHUh?=
SK-MEL-1 NHfOeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjEOFBbUUN3ME21MlI6ODR2IN88US=> NG\XeIZUSU6JRWK=
EW-22 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwMkm0OlYh|ryP NI\tdotUSU6JRWK=
MZ7-mel M3\lXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwNEC2PVEh|ryP MoXyV2FPT0WU
LP-1 M2q5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTz[VllUUN3ME21MlQyOjlzIN88US=> MnO2V2FPT0WU
NCI-SNU-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTGd2NKSzVyPUWuOlQxPzRizszN MnLyV2FPT0WU
LU-65 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPybm9KSzVyPUWuO|Y{PzNizszN M4jRbnNCVkeHUh?=
CW-2 M2TZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVwOEW5OVkh|ryP M3TRcXNCVkeHUh?=
WSU-NHL NWDUd3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX74dZBxUUN3ME21Mlk2OTd2IN88US=> MmPGV2FPT0WU
IST-MES1 NXL4dlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHnNpVMUUN3ME21Mlk2PDR|IN88US=> NXn6N3I5W0GQR1XS
U-266 NFX1R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1TWM2OD13Lkm4NlAzKM7:TR?= M4XpdnNCVkeHUh?=
TALL-1 NEm3ZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwMUS2PFgh|ryP MVnTRW5ITVJ?
Calu-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjYVGZKSzVyPU[uNVU{OTZizszN MYfTRW5ITVJ?
MMAC-SF NXHOV5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XWmlEPTB;Nj6xPFU2PiEQvF2= MnPsV2FPT0WU
NCI-H82 NHjlXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTZwMkC0PFkh|ryP MYTTRW5ITVJ?
RS4-11 NHvTOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrER|FRUUN3ME22MlI2QDl5IN88US=> NUe1PZRyW0GQR1XS
SNU-C2B NXHuVmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZwNEC5Olkh|ryP NXnwV3VOW0GQR1XS
BOKU NVfwSYhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwNEe1PVch|ryP NHfkb4RUSU6JRWK=
C8166 NF\CfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTZwNUW5NVIh|ryP MVjTRW5ITVJ?
D-247MG MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml35TWM2OD15LkC0N|Q4KM7:TR?= MkjYV2FPT0WU
EW-18 NF3wU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDTTWM2OD15LkC3NlkzKM7:TR?= NVvPSWlnW0GQR1XS
KG-1 M3vT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn0TWM2OD15Lk[yO|M5KM7:TR?= NVTtUWdHW0GQR1XS
REH NH7EemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HGZWlEPTB;Nz62PFExQSEQvF2= MmLIV2FPT0WU
U-698-M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC4eVlKSzVyPUeuPFQ{OTVizszN NFiwZlNUSU6JRWK=
KP-N-RT-BM-1 NIHOZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHhWJh4UUN3ME23Mlk{ODJ7IN88US=> NXrVUINWW0GQR1XS
MS-1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XZfWlEPTB;Nz65OlA1OSEQvF2= NUnhWY1xW0GQR1XS
SNU-C1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpPWlEPTB;Nz65PFE6OiEQvF2= NGHnTmRUSU6JRWK=
SK-MM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThwMk[wOlUh|ryP MVzTRW5ITVJ?
LAN-6 NUn6bGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPhV5ZkUUN3ME24MlMxODBzIN88US=> M4TJSnNCVkeHUh?=
NEC8 NH\IbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvW[G9xUUN3ME24MlMxPjlzIN88US=> NIHhfVRUSU6JRWK=
NCI-H1770 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTITWM2OD16LkO4NFAzKM7:TR?= NHT1dlRUSU6JRWK=
D-336MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwNECxNVYh|ryP NXPHPYpzW0GQR1XS
COLO-829 NWmzSWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRThwNEi4O|kh|ryP M{e4cnNCVkeHUh?=
LS-513 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHqbnkyUUN3ME24MlU6PTl7IN88US=> NV64XnpnW0GQR1XS
YT MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRThwNkK0Nlch|ryP NGTKc4pUSU6JRWK=
EW-24 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjZVolGUUN3ME24Mlc3PTRizszN M4S5PXNCVkeHUh?=
IST-SL1 NXPoWXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjSO4ZKSzVyPUiuPFY2PDNizszN NVTSXlhbW0GQR1XS
CA46 NYL1NG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnhNmdKSzVyPUiuPVUxQThizszN NIPSPHlUSU6JRWK=
NCI-H1838 NHjPbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD16Lkm4OlAzKM7:TR?= NVfT[3R3W0GQR1XS
NCI-H719 NXz2[4pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1TWM2OD17LkK1Nlc6KM7:TR?= M{fqbnNCVkeHUh?=
HCE-T MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[w[llzUUN3ME25MlMxQDVzIN88US=> NET2V5VUSU6JRWK=
A498 M1fjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPb5N{UUN3ME25MlM3OTJ2IN88US=> M13RNnNCVkeHUh?=
LB831-BLC NF;heYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXSeoZJUUN3ME25Mlc3PTJzIN88US=> Mnv5V2FPT0WU
SKM-1 NHnad|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTlwOEW5OlMh|ryP NVPBOGlRW0GQR1XS
THP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TLSmlEPTB;OT65OlkyQCEQvF2= Mmj5V2FPT0WU
SHP-77 NUXpU|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTkTWM2OD1zMD60NFch|ryP M1jHTXNCVkeHUh?=
EW-3 NVPKUG1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\RTWM2OD1zMD62Nlg6KM7:TR?= Mo[2V2FPT0WU
KY821 NHvoR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;HNmlEPTB;MUCuO|Y{KM7:TR?= M{DrNHNCVkeHUh?=
NCI-SNU-1 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jiOWlEPTB;MUGuNFIyPyEQvF2= MV3TRW5ITVJ?
HCC2218 M3vrSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXVZ|RKSzVyPUGxMlM6QDZizszN NXXzWZNvW0GQR1XS
IM-9 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFzLkWxNFYh|ryP MlTvV2FPT0WU
NCI-H889 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLDeoVpUUN3ME2xNU42OzF|IN88US=> M3rOXXNCVkeHUh?=
HDLM-2 M1v0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXiU2NKSzVyPUGyMlQyPTlizszN NYHiVIhoW0GQR1XS
LB2518-MEL MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKTWJ4UUN3ME2xNk43QDF3IN88US=> MX3TRW5ITVJ?
NCI-H23 M3\hPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3OZVI5UUN3ME2xN{4zPDJ3IN88US=> MYfTRW5ITVJ?
NB17 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHncFRKSzVyPUGzMlQ2PzlizszN NHzMemVUSU6JRWK=
NCI-H322M MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHyPWxKUUN3ME2xOE41ODZ6IN88US=> M4iyRnNCVkeHUh?=
SUP-T1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxXlNKSzVyPUG0MlQyOyEQvF2= M33D[HNCVkeHUh?=
ES3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[5OG1KSzVyPUG1MlA4ODNizszN M3HIUXNCVkeHUh?=
ES5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjnWZNSUUN3ME2xOU4xPzh5IN88US=> MnHSV2FPT0WU
NCI-H1650 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnU[2EyUUN3ME2xOU41QTd7IN88US=> MYTTRW5ITVJ?
NCI-H226 NWr1[lJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn60TWM2OD1zNT64O|Y5KM7:TR?= M1jIfXNCVkeHUh?=
COR-L88 NXP3TpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXQRYExUUN3ME2xOk4{OTRizszN MYXTRW5ITVJ?
SCC-15 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy1T3RTUUN3ME2xOk4{QDZ7IN88US=> NYDReXBUW0GQR1XS
GOTO NFHIS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTk[2REUUN3ME2xOk41Pzl|IN88US=> MVTTRW5ITVJ?
SIMA NEHLPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqzTWM2OD1zNj60PFAzKM7:TR?= NHHZe49USU6JRWK=
NCI-H1299 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFziNpRKSzVyPUG3MlE2QTFizszN MnjpV2FPT0WU
NCI-H1581 NIjMO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1zNz60NlE6KM7:TR?= NIrrT3FUSU6JRWK=
MHH-NB-11 NXzyXYlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6yTWM2OD1zNz65Olg{KM7:TR?= NIXyVHFUSU6JRWK=
MFM-223 M3HtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DNW2lEPTB;MUiuNFU{QCEQvF2= Ml\aV2FPT0WU
ES7 NIjhUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF6LkW0N|Eh|ryP M3rwfnNCVkeHUh?=
JVM-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXTTWM2OD1zOD63NVch|ryP MVzTRW5ITVJ?
RL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ZNGlEPTB;MkCuN|g5KM7:TR?= M37ZbHNCVkeHUh?=
EC-GI-10 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLVTWM2OD1{MT6yNFQyKM7:TR?= NIPTcY9USU6JRWK=
LNCaP-Clone-FGC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TuOmlEPTB;MkGuOlc3QCEQvF2= MmH5V2FPT0WU
IMR-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBc|JKSzVyPUKxMlg1QTRizszN NXv6cpVTW0GQR1XS
KP-N-YS NVfUdVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[wdlNKSzVyPUKxMlg4PSEQvF2= M3mwS3NCVkeHUh?=
Mo-T NEW0OZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonITWM2OD1{Mj6yNVg2KM7:TR?= MVjTRW5ITVJ?
NCI-H128 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL2cWNJUUN3ME2yN{42QDV|IN88US=> MlrpV2FPT0WU
RH-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fscmlEPTB;MkOuO|g3PiEQvF2= NEHJVWlUSU6JRWK=
NCI-H2171 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvITWM2OD1{ND6yOFg2KM7:TR?= M4P5[HNCVkeHUh?=
RPMI-8866 NIjZeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jXdWlEPTB;Mk[uO|QzKM7:TR?= M2jBc3NCVkeHUh?=
SK-N-FI MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ5LkO4NVEh|ryP NGLMcppUSU6JRWK=
LOXIMVI MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJ5LkiwOVEh|ryP M3;LZnNCVkeHUh?=
P31-FUJ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TXWGlEPTB;M{GuOVM4PCEQvF2= MmrXV2FPT0WU
KMS-12-PE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR7LkWzNFIh|ryP NEXJ[5JUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 3年-20℃
2年-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β抑制剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt抑制剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • Everolimus (RAD001)

    Everolimus (RAD001)は一種のmTOR抑制剤で、FKBP12に作用します。無細胞試験でIC50値は1.6-2.4 nMになります。

  • AZD8055

    AZD8055は一種の新たなATP競争性mTOR抑制剤で、MDA-MB-468細胞の中でIC50値は0.8 nMです。AZD8055はmTORに作用する選択性はPI3K亜型とATM/DNA-PKに作用する選択性より約1000倍が高くなります。臨床1期。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1は一種の有効なmTORC1/2抑制剤で、無細胞試験でIC50値が2 nM/10 nMになって、mTORに作用する選択性はPI3Kに作用する選択性より1000倍が高くなります。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は一種の特定なmTOR抑制剤で、無細胞試験でIC50値は1.76 μMです。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は一種の有効的で、選択性mTOR抑制剤で、無細胞試験でこのIC50値が1 nMです。INK 128 (MLN0128)はmTORに作用する効果はI型PI3K亜型に作用する効果より200倍以上が高くなります。ラパマイシン(Rapamycin)に比べて、INK 128 (MLN0128)は優先にmTORC1/2を抑制し、促侵入遺伝子( pro-invasion genes )に敏感です。臨床1期。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ